CSPC Pharmaceutical Group Limited (CVG) — Working Capital to Net Assets Ratio
CSPC Pharmaceutical Group Limited (CVG) has a Working Capital to Net Assets ratio of 34.9% as of December 2025. Working capital of €12.07 Billion (current assets of €22.25 Billion minus current liabilities of €10.18 Billion) is measured against net assets of €34.55 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See CSPC Pharmaceutical Group Limited free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
CSPC Pharmaceutical Group Limited Working Capital to Net Assets (2013–2025)
This chart shows how CSPC Pharmaceutical Group Limited's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 34.9%, reflecting working capital of €12.07 Billion against net assets of €34.55 Billion EUR. See CSPC Pharmaceutical Group Limited defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for CSPC Pharmaceutical Group Limited (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for CSPC Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of CSPC Pharmaceutical Group Limited.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 34.9% | €12.07 Billion | €34.55 Billion | €22.25 Billion | €10.18 Billion | ▼ -1.2 pp |
| 2024 | 36.2% | €12.25 Billion | €33.87 Billion | €21.89 Billion | €9.63 Billion | ▼ -11.1 pp |
| 2023 | 47.3% | €16.56 Billion | €35.02 Billion | €26.74 Billion | €10.18 Billion | ▼ -0.1 pp |
| 2022 | 47.4% | €15.00 Billion | €31.64 Billion | €23.96 Billion | €8.96 Billion | ▼ -1.5 pp |
| 2021 | 48.9% | €13.11 Billion | €26.83 Billion | €20.34 Billion | €7.23 Billion | ▲ +7.2 pp |
| 2020 | 41.6% | €9.62 Billion | €23.10 Billion | €15.92 Billion | €6.30 Billion | ▲ +3.4 pp |
| 2019 | 38.2% | €7.46 Billion | €19.52 Billion | €13.70 Billion | €6.24 Billion | ▼ -4.1 pp |
| 2018 | 42.3% | €6.56 Billion | €15.50 Billion | €13.80 Billion | €7.25 Billion | ▼ -18.9 pp |
| 2017 | 61.2% | €7.87 Billion | €12.87 Billion | €13.63 Billion | €5.76 Billion | ▲ +13.6 pp |
| 2016 | 47.6% | €4.34 Billion | €9.13 Billion | €8.43 Billion | €4.08 Billion | ▲ +0.4 pp |
| 2015 | 47.2% | €4.16 Billion | €8.81 Billion | €7.65 Billion | €3.48 Billion | ▲ +10.4 pp |
| 2014 | 36.8% | €3.00 Billion | €8.15 Billion | €6.61 Billion | €3.60 Billion | ▲ +3.5 pp |
| 2013 | 33.4% | €2.53 Billion | €7.60 Billion | €6.37 Billion | €3.84 Billion | — |